1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

NCT01162785 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: SCH 721015

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]